Literature DB >> 7928495

Pretreatment oxygenation profiles of human soft tissue sarcomas.

D M Brizel1, G L Rosner, J Harrelson, L R Prosnitz, M W Dewhirst.   

Abstract

PURPOSE: Tumor oxygenation is thought to influence the radiocurability of many malignancies. Advances in polarographic electrode technology have facilitated the in situ measurement of human tumor pO2. The optimal method of defining a "hypoxic" tumor is not known. Characterization of intra-tumor and intertumor pO2 heterogeneity could help with this process. This study was performed to evaluate pretreatment tumor oxygenation status and pO2 heterogeneity in patients with soft tissue sarcoma. METHODS AND MATERIALS: Nine patients with soft tissue sarcomas underwent pretreatment pO2 measurements with the Eppendorf pO2 histograph. Two grossly distinct anatomic sites within each tumor were measured in all but one patient; these were localized under computerized tomography guidance to ensure that all measurements were obtained from tumor tissue. Multiple probe tracks were studied at each site. Measurements were performed in resting, awake patients.
RESULTS: A total of 1588 pO2 readings was obtained (mean = 176/patient). Measurement path lengths ranged from 22-36 mm. The average hypoxic fraction (pO2 < 5 mm Hg) was 29% (range 0-76%). Arterial pO2 was positively correlated with mean and median tumor pO2. Tumor hypoxic fraction increased with increasing tumor volume. Linear pO2 profiles and frequency histograms provided similar estimates of the extent of hypoxia in individual tumors. Marked variation in oxygenation existed both within and between individual tumors. The intertumor variation was greater than the intratumor variation.
CONCLUSION: Radiobiologic hypoxia exists in human soft tissue sarcomas. The pO2 variation within individual tumors is less than the variation between tumors. Further study is necessary to identify the best parameter for defining tumor hypoxia and to discern the relationship between tumor pO2 and treatment outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928495     DOI: 10.1016/0360-3016(92)90950-m

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

Authors:  Min Yang; Haokao Gao; Xilin Sun; Yongjun Yan; Qimeng Quan; Wendy Zhang; Khalid A Mohamedali; Michael G Rosenblum; Gang Niu; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2011-02-15       Impact factor: 4.939

2.  [Oxygen pressure distribution in lymph node metastases and the changes during acute respiratory hypoxia].

Authors:  V Strnad; L Keilholz; M Kirschner; M Meyer; R Sauer
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

Review 3.  Biological validation of electron paramagnetic resonance (EPR) image oxygen thresholds in tissue.

Authors:  Inna Gertsenshteyn; Mihai Giurcanu; Peter Vaupel; Howard Halpern
Journal:  J Physiol       Date:  2020-06-28       Impact factor: 5.182

4.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Authors:  Sant P Chawla; Lee D Cranmer; Brian A Van Tine; Damon R Reed; Scott H Okuno; James E Butrynski; Douglas R Adkins; Andrew E Hendifar; Stew Kroll; Kristen N Ganjoo
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

5.  Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET.

Authors:  Kelin Wang; Ellen Yorke; Sadek A Nehmeh; John L Humm; C Clifton Ling
Journal:  Med Phys       Date:  2009-10       Impact factor: 4.071

Review 6.  Blood flow and oxygenation status of human tumors. Clinical investigations.

Authors:  H J Feldmann; M Molls; P Vaupel
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

7.  Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.

Authors:  Nancy Lee; Sadek Nehmeh; Heiko Schöder; Matthew Fury; Kelvin Chan; C Clifton Ling; John Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

8.  Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.

Authors:  Fuqiu He; Xuelong Deng; Bixiu Wen; Yueping Liu; Xiaorong Sun; Ligang Xing; Akiko Minami; Yunhong Huang; Qing Chen; Pat B Zanzonico; C Clifton Ling; Gloria C Li
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

Review 9.  Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia.

Authors:  Simon P Robinson; John R Griffiths
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

10.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.